- Home
- CSTL vs SNDA Comparison
CSTL vs SNDA Comparison
Compare CSTL & SNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- SNDA
- Stock Information
- Founded
- CSTL 2007
- SNDA 1990
- Country
- CSTL United States
- SNDA United States
- Employees
- CSTL 784
- SNDA N/A
- Industry
- CSTL Medical Specialities
- SNDA Hospital/Nursing Management
- Sector
- CSTL Health Care
- SNDA Health Care
- Exchange
- CSTL Nasdaq
- SNDA Nasdaq
- Market Cap
- CSTL 456.2M
- SNDA 494.5M
- IPO Year
- CSTL 2019
- SNDA 1997
- Fundamental
- Price
- CSTL $15.95
- SNDA $24.49
- Analyst Decision
- CSTL Strong Buy
- SNDA Hold
- Analyst Count
- CSTL 6
- SNDA 1
- Target Price
- CSTL $37.67
- SNDA $26.00
- AVG Volume (30 Days)
- CSTL 527.3K
- SNDA 36.5K
- Earning Date
- CSTL 05-05-2025
- SNDA 05-12-2025
- Dividend Yield
- CSTL N/A
- SNDA N/A
- EPS Growth
- CSTL N/A
- SNDA N/A
- EPS
- CSTL N/A
- SNDA N/A
- Revenue
- CSTL $347,083,000.00
- SNDA $290,215,000.00
- Revenue This Year
- CSTL N/A
- SNDA $22.33
- Revenue Next Year
- CSTL $1.80
- SNDA $6.31
- P/E Ratio
- CSTL N/A
- SNDA N/A
- Revenue Growth
- CSTL 38.43
- SNDA 21.71
- 52 Week Low
- CSTL $15.45
- SNDA $19.34
- 52 Week High
- CSTL $35.84
- SNDA $33.25
- Technical
- Relative Strength Index (RSI)
- CSTL 33.63
- SNDA 50.35
- Support Level
- CSTL $15.45
- SNDA $24.23
- Resistance Level
- CSTL $16.43
- SNDA $25.15
- Average True Range (ATR)
- CSTL 0.59
- SNDA 0.72
- MACD
- CSTL 0.04
- SNDA -0.23
- Stochastic Oscillator
- CSTL 15.93
- SNDA 7.44
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About SNDA Sonida Senior Living Inc.
Sonida Senior Living Inc is an owner operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.